Farydak (Panobinostat)
- Medicine Name: Farydak
- Generic Name: Panobinostat
- Dosage Form & Strength: Capsules: 10mg/15mg/20mg
- Manufactured By: Novartis Pharmaceuticals Corporation
Farydak, a histone deacetylase inhibitor, in combination with drugs bortezomib and dexamethasone, is used to treat patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent.
Recommended Dosage: The recommended starting dose of Farydak capsules is 20 mg, taken orally once every other day at about the same time, either with or without
food for 3 doses per week in Weeks 1 and 2 of each 21 day cycle for up to 8 cycles. Consider continuing therapy for an additional 8 cycles for patients with clinical benefit who do not experience unresolved severe or medically significant toxicity. The total duration of treatment may be up to 16 cycles (48 weeks). Farydak is administered in combination with drugs bortezomib and dexamethasone. The recommended dosage of bortezomib is 1.3 mg/m2 administered as an injection. The recommended dosage of dexamethasone is 20 mg taken by mouth (orally) per scheduled day, on a full stomach.
In case a dose is missed it can be taken up to 12 hours after the specified dose time. In case vomiting occurs the patient should not repeat the dose, but should take the next usual scheduled dose.
- Severe diarrhea occurred in patients treated with panobinostat 20 mg capsule. Monitor patient hydration status and electrolyte blood levels, including magnesium, potassium and phosphate, weekly during therapy and correct to prevent dehydration and electrolyte disturbances. Initiate anti-diarrheal medicine at the onset of diarrhea.
- Severe and fatal cardiac ischemic events, as well as severe arrhythmias, and electrocardiogram (ECG) changes emerged in patients taking panobinostat. Obtain ECG periodically during treatment. Electrolytes should be monitored throughout the treatment and abnormalities should be corrected as clinically indicated.
- Farydak 20 mg capsules cause myelosuppression, including severe thrombocytopenia, neutropenia and anemia. Obtain CBC and monitor the CBC weekly during therapy (or more frequently if clinically indicated). Monitor CBCs more frequently in patients aged over 65 years due to the increased frequency of myelosuppression in these patients.
- Localized and systemic infections, including bacterial infections, pneumonia, invasive fungal infections, and viral infections may occur in patients taking Farydak 10 mg or any other dosage strength. Monitor patients for signs/symptoms of infections during therapy; if a diagnosis of infection is made, institute apt anti-infective treatment promptly and consider interruption or discontinuation of this treatment.
- Hepatic dysfunction, primarily elevations in the aminotransferases and total bilirubin, emerged in patients treated with panobinostat. Liver function should be monitored before starting treatment and regularly throughout the treatment.
- Panobinostat can cause fetal harm if used by a pregnant woman. This drug was teratogenic in rats and rabbits. If it is used during pregnancy, or if the patient becomes pregnant while taking it, the patient should be apprised of the potential hazard to the fetus.
What documents are required to import FARYDAK to India?
FARYDAK (panobinostat) capsules can be imported by patients or government hospitals on the name of the patients only.
The following documentation needed to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients Identity Proof (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is FARYDAK available in India?
FARYDAK (panobinostat capsules) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability of Farydak in India (Mumbai, Kolkata, Chennai, Hyderabad, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
FARYDAK can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of FARYDAK (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for Farydak price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
What is the Generic Name for the brand/trade name drug Farydak®?
Panobinostat is Generic Name for the trade name drug Farydak®.
Is Farydak® approved by the FDA?
Yes, Farydak® is approved by the FDA. Date of approval: February 23, 2015.
What should I avoid while on Farydak®?
Avoid star fruit, pomegranate or pomegranate juice, and grapefruit or grapefruit juice while on Farydak. These foods may affect the level of Farydak in the blood.
What is the dosage and form of Farydak® supplied?
Farydak® is supplied as Capsules: 10mg/15mg/20mg for oral administration.
What are the most common side effects due to Farydak®?
Most common side effects due to Farydak® include: nausea, diarrhea, fatigue, peripheral edema, decreased appetite, vomiting, and pyrexia.
How much does Farydak cost in India?
The farydak cost in India is reasonable and can vary. To procure this multiple myeloma medication authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Farydak®?
Store Farydak between 68°F to 77°F (20°C to 25°C). Store blister packs in the original carton to protect from light.
What are the Highlights of prescribing information for Farydak®?
Click Here to download full Farydak prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.